

Cladribine Tablets Effects on T Cell Subsets in Patients with Early MS

Disclosure Statement

This study was sponsored by EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany (in the USA), and Merck Serono SA – Geneva, an affiliate of Merck KGaA Darmstadt, Germany (ROW).

Author Disclosure Statement

OS serves on the editorial boards of JAMA Neurology, Multiple Sclerosis Journal, and Therapeutic Advances in Neurological Disorders; has served on data monitoring committees for Pfizer and TG Therapeutics without monetary compensation; has advised Genzyme and Novartis, and has participated in a Teva-sponsored meeting; currently receives grant support from Teva Pharmaceuticals and Opexa Therapeutics; is funded by a Merit Review grant (federal award document number (FAIN) I01BX001674) from the United States (U.S.) Department of Veterans Affairs, Biomedical Laboratory Research and Development. **PS-S** has served on advisory boards for Biogen, Merck, Novartis, TEVA, MedDay Pharmaceuticals and GSK; on steering committees or independent data monitoring boards in trials sponsored by Merck, TEVA, GSK and Novartis; has received speaker honoraria from Biogen Idec, Merck, TEVA, Sanofi-Aventis, Genzyme, and Novartis. His department has received research support from Biogen, Merck, TEVA, Novartis, Roche and Genzyme. **TL** has received consultancy fees or clinical research grants from Acorda, Bayer, Biogen, Daiichi, EMD Serono, Novartis, ONO, Pfizer, Teva Neuroscience. **YH, DD** and **UB** are employees of EMD Serono, Inc., Billerica, USA, a business of Merck KGaA, Darmstadt, Germany.